| Company Name: | Bovie Medical | | Ticker Symbol: | BVX | | | WWW Address: | www.boviemedical.com | | CEO: | Andrew Makrides | | No. of Employees: | 174 | | Common Issue Type: | CS | | Business Description: | A medical device company engaged in the manufacturing and marketing of electrosurgical devices.
|
| | | Industry Information: | HEALTH SERVICES - Medical Instruments & Supplies [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 8.15 |  0.12 | 7.37 | 8.93 | 8.25 | 8.25 | 8.01 | 38200 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 139.4 | 17.1 | 0.51 | 0.11 | 0.00 | 203.8 | 0.0 | 10.00 - 4.00 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 8.15 | $ | | PE Ratio - LTM | 203.8 | |
| Market Capitalisation | 139.3 | mil |
| Latest Shares Outstanding | 17.1 | mil |
| Earnings pS (EPS) | 0.11 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | 0 | % |
| Revenue per Employee | 161,474 | $ |
| Effective Tax Rate | 34.0 | % |
| Float | 15.2 | mil |
| Float as % of Shares Outstanding | 89.0 | % |
| Foreign Sales | 0 | mil |
| Domestic Sales | 0 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 33.40 | % |
| Research & Devlopment (R&D) as % of Revenue | 7.70 | % |
| Gross Profit Margin | 48.0 | % |
| EBITDA Margin | 6.8 | % |
| Pre-Tax Profit Margin | 3.0 | % |
| Assets Turnover | 1.1 | % |
| Return on Assets (ROA) | 2.2 | % |
| Return on Equity (ROE) | 3.1 | % |
| Return on Capital Invested (ROCI) | 2.6 | % |
| Current Ratio | 4.3 | |
| Leverage Ratio (Assets/Equity) | 1.4 | |
| Interest Cover | 7.6 | |
| Total Debt/Equity (Gearing Ratio) | 0.27 | |
| LT Debt/Total Capital | 17.0 | % |
| Working Capital pS | 0.59 | $ |
| Cash pS | 0.17 | $ |
| Book-Value pS | 1.14 | $ |
| Tangible Book-Value pS | 0.85 | $ |
| Cash Flow pS | 0.10 | $ |
| Free Cash Flow pS | -0.18 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 7.15 | |
| Price/Tangible Book Ratio | 9.62 | |
| Price/Cash Flow | 85.0 | |
| Price/Free Cash Flow | -44.7 | |
| P/E as % of Industry Group | 719.0 | % |
| P/E as % of Sector Segment | 406.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 0.7 | 101 | 300 | 1,400 |
| 4 Weeks | 8.58 | 7.89 | 8.26 | -1.3 | 98 | 315 | 6,300 |
| 13 Weeks | 9.43 | 7.04 | 9.44 | -13.7 | 81 | 422 | 26,995 |
| 26 Weeks | 10.00 | 6.70 | 7.40 | 10.1 | 90 | 674 | 85,655 |
| 52 Weeks | 10.00 | 4.00 | 4.34 | 87.8 | 138 | 524 | 131,601 |
| YTD | 10.00 | 5.75 | - | 30.6 | 108 | 544 | 122,340 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 8.24 | 8.19 | 8.05 | 8.11 | 7.70 | 0.51 | 0.60 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 7.79 | 73.7 | 1.69 |
| Income | 3.10 | 0.8 | -29.76 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 51.37 | NA | 55.92 |
| R&D | 21.71 | NA | 23.27 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | -2.6 | -12.7 | -2.4 |
| Earnings % | -68.3 | -100.0 | -23.7 |
| EPS % | -70.0 | -100.0 | -21.4 |
| EPS $ | -0.07 | -0.02 | -0.03 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 38.00 |
| Current Ratio | 5.2 |
| Quick Ratio (Acid Test) | 2.4 |
| Liquidity Ratio (Cash) | 1.11 |
| Receivables Turnover | 10.2 |
| Average Collection Period | 35 |
| Working Capital/Equity | 52.1 |
| Working Capital pS | 0.59 |
| Cash-Flow pS | 0.17 |
| Free Cash-Flow pS | -0.23 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 13.98 |
| Financial Leverage Ratio (Assets/Equity) | 1.4 |
| Debt Ratio | 27.1 |
| Total Debt/Equity (Gearing Ratio) | 0.21 |
| LT Debt/Equity | 0.21 |
| LT Debt/Capital Invested | 20.6 |
| LT Debt/Total Liabilities | 55.4 |
| Interest Cover | 48.5 |
| Interest/Capital Invested | 0.25 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 23.84 |
| Tobin's Q Ratio | 5.40 |
| Current P/E Ratio - LTM | 203.80 |
| Enterprise Value (EV)/EBITDA | 63.48 |
| Enterprise Value (EV)/Free Cash Flow | -43.61 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 9.62 |
| Price/Book Ratio - LTM | 7.15 |
| Price/Cash Flow Ratio | 85.0 |
| Price/Free Cash Flow Ratio - LTM | -44.7 |
| Price/Sales Ratio | 5.06 |
| P/E Ratio (1 month ago) - LTM | 212.5 |
| P/E Ratio (26 weeks ago) - LTM | 56.9 |
| P/E Ratio (52 weeks ago) - LTM | 33.4 |
| 5-Y High P/E Ratio | 101.7 |
| 5-Y Low P/E Ratio | 17.8 |
| 5-Y Average P/E Ratio | 57.3 |
| Current P/E Ratio as % of 5-Y Average P/E | 355 |
| P/E as % of Industry Group | 719.0 |
| P/E as % of Sector Segment | 406.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 0.23 |
| Current Liabilities pS | 0.14 |
| Tangible Book Value pS - LTM | 0.85 |
| Book Value pS - LTM | 1.14 |
| Capital Invested pS | 1.33 |
| Cash pS - LTM | 0.17 |
| Cash Flow pS - LTM | 0.10 |
| Free Cash Flow pS - LTM | -0.18 |
| Earnings pS (EPS) | 0.11 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -13.45 |
| Free Cash Flow Margin 5YEAR AVG | -1.77 |
| Net Profit Margin | 6.5 |
| Net Profit Margin - 5YEAR AVRG. | 6.9 |
| Equity Productivity | 1.50 |
| Return on Equity (ROE) | 9.7 |
| Return on Equity (ROE) - 5YEAR AVRG. | 12.5 |
| Capital Invested Productivity | 1.24 |
| Return on Capital Invested (ROCI) | 8.1 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | 11.8 |
| Assets Productivity | 1.30 |
| Return on Assets (ROA) | 7.1 |
| Return on Assets (ROA) - 5YEAR AVRG. | 10.2 |
| Gross Profit Margin | 48.0 |
| Gross Profit Margin - 5YEAR AVRG. | 42.3 |
| EBITDA Margin - LTM | 6.8 |
| EBIT Margin - LTM | 3.5 |
| Pre-Tax Profit Margin | 9.9 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 7.6 |
| Effective Tax Rate | 34.0 |
| Effective Tax Rate - 5YEAR AVRG. | 7.3 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 160 |
| Revenue per Employee | 161,474 |
| Net Income per Employee | 10,528 |
| Average Collection Period | 38 |
| Receivables Turnover | 10.2 |
| Day's Inventory Turnover Ratio | 122 |
| Inventory Turnover | 2.9 |
| Inventory/Sales | 20.8 |
| Accounts Payble/Sales | 5.13 |
| Assets/Revenue | 0.77 |
| Net Working Capital Turnover | 2.87 |
| Fixed Assets Turnover | 2.06 |
| Total Assets Turnover | 1.3 |
| Revenue per $ Cash | 10.96 |
| Revenue per $ Plant | 3.94 |
| Revenue per $ Common Equity | 1.50 |
| Revenue per $ Capital Invested | 1.24 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 30.2 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 27.9 |
| Research & Devlopment (R&D) as % of Revenue | 7.3 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 7.3 |
|
|  
|
| |
 |  |